Outcome of Surgical Resection for Pathologic N0 and Nx Non-small Cell Lung Cancer  by Osarogiagbon, Raymond U. et al.
ORIGINAL ARTICLE
Outcome of Surgical Resection for Pathologic N0 and Nx
Non-small Cell Lung Cancer
Raymond U. Osarogiagbon, MBBS, FACP,*† Jeffrey W. Allen, MD,*† Aamer Farooq, MD,†
Allen Berry, MD,‡ David Spencer, MD,§ and Thomas O’Brien, MD
Purpose:Metastasis to lymph nodes (LNs) connotes poor prognosis
in non-small cell lung cancer (NSCLC). Sufficient LNs must be
examined to accurately determine LN negativity. Patients with no
LNs examined (pNx) have an indeterminate stage, may have unde-
tected disease and erroneous assignment to a low-risk group. To
evaluate this possibility, we compared the survival of patients with
node-negative disease and at least one LN examined (pN0) to those
with pNx.
Methods: Retrospective analysis of all resections for NSCLC from
January 1, 2004 to December 31, 2007 at hospitals in the Memphis
Metropolitan Area.
Results: Of 746 resections, 90 (12.1%) were Nx; 506 (67.8%) N0.
Demographic and histologic characteristics were similar. A total of
54.4% Nx patients had sublobar resection, compared with 5.5% N0
(p  0.0001). In the N0 cohort, the median (range) number of LNs
was 5 (1–45); N1 LNs, 3 (0–38); N2 LNs, 1 (0–29); 35.4% had no
mediastinal LNs examined; 9.1% had only mediastinal LNs. Eighty-
five percent of N0 patients had less than 10 LNs. The 3-year survival
estimate for the T1NxM0 versus T1N0M0 patients was 70% versus
79% (p  0.17); for T2NxM0 versus T2N0M0, it was 25% versus
65% (p  0.01).
Conclusions: A high percentage of patients undergoing surgical
resection for NSCLC have no LNs examined, most of these patients
have had sublobar resection. Majority with node-negative disease
have fewer than 10 LNs, a large proportion have no mediastinal
LNs, raising the possibility of understaging. Patients with pT2Nx do
significantly worse than those with pT2N0.
Key Words: Quality of care, Lymph node staging, Survival, Sur-
gical resection, Outcomes research, Early stage.
(J Thorac Oncol. 2010;5: 191–196)
Lymph node metastasis is the most important determinantof long-term prognosis after surgical resection of non-
small cell lung cancer (NSCLC). Five-year survival rates for
patients with pathologic N0, N1, N2, and N3 NSCLC are
56%, 38%, 22%, and 6% respectively.1 Noninvasive evalua-
tion of lymph node (LN) status, clinical N staging, is unre-
liable.2,3 Although clinically useful, radiologic studies such as
computed tomography and positron emission tomography/
computed tomography scans, have significant sensitivity and
specificity limitations.4,5 It is not surprising, therefore, that
pathologic staging obtained at thoracotomy is significantly
more accurate than radiologic staging.6 This is reflected in the
higher survival statistics of pathologically staged patients
over clinically staged patients of identical stage.7,8
Furthermore, size of neither the primary tumor9,10 nor
the LN11,12 is a sufficiently reliable predictor of metastatic LN
involvement to justify elimination of mediastinal LN exam-
ination below a size threshold.13 Small LNs frequently con-
tain metastatic disease, and large LNs might be reactive. LNs
with metastatic cancer might not feel different than those
without. Even micrometastatic LN disease is predictive of
adverse prognosis.14
Given the importance of pathologic stage in determin-
ing prognosis and postoperative adjuvant therapy, and the
difficulty in predicting the likelihood and extent of LN
involvement, it is believed that curative-intent surgery for
lung cancer requires that as many hilar/intrapulmonary (N1)
and mediastinal (N2) LNs as possible should be examined
after resection to accurately determine the pathologic stage
and, possibly, to avoid leaving involved LNs behind.15 This
belief is supported by the significant correlation between the
number of LNs examined after lung cancer resection and
outcomes, both for node-negative16,17 and node-positive pa-
tients.18 The American Joint Committee on Cancer (AJCC)
tumor, node, metastasis staging system recognizes that in-
volvement of N2 nodes connotes a worse prognosis than
involvement of N1 nodes. However, the number of LNs
involved is also a powerful predictor of prognosis, irrespec-
tive of N1 or N2 location.18–20 This fact is not currently
reflected in the AJCC tumor, node, metastasis staging system.
Analyses of the correlation between the number of LNs
examined and outcomes have usually excluded patients who
had no LNs examined (pathologic Nx).16 In clinical practice,
these patients are often treated as though they had N0 disease,
because of the prohibitive risk of reattempting a more exten-
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sive lymph nodal dissection. Surgical resection without LN
harvest introduces needless uncertainty into staging and runs
the risk of leaving disease behind.
We compared the characteristics and outcomes of pa-
tients who underwent surgical resection for NSCLC with no
LNs examined (pNx) to patients of similar T and M stages
who had at least one LN examined (pN0) in the Memphis
Metropolitan Area Quality of Surgical Resection (MMA-
QSR) cohort. Our goal was to estimate the prevalence of
suboptimal nodal staging, as well as the circumstances and
risk associated with this practice. The study was approved by
the Institutional Review Board (IRB) of the University of
Tennessee Health Sciences Center, as well as the IRB of all
hospitals where surgery was performed. All IRBs provided a
waiver of informed consent for this study.
METHODS
Patients
We retrospectively analyzed the clinical records of all
patients who underwent surgical resection for lung cancer in
the greater Memphis Metropolitan Area from January 1, 2004
to December 31, 2007. Patients were identified through a
search of pathology databases at hospitals in the Memphis
Metropolitan Area. Patients who had lung resection for be-
nign and nonlung primary metastatic disease and those who
had preoperative chemotherapy or radiotherapy were ex-
cluded from this analysis. Those with bronchioloalveolar cell,
small cell, and carcinoid tumors were excluded from the
analysis of survival. Death information was obtained from
hospital records and search of the National Death Index by
trained clerical staff.
Statistical Analysis
Variables were compared with the 2 test or Fisher’s
exact test. Group medians were compared using the Wilcoxon-
Mann-WhitneyU test. Survival estimates were calculated by the
Kaplan-Meier method and compared using the log-rank test. The
Cox proportional hazards model was used to compare the hazard
between N-stage groups while controlling for other variables.
The p values less than 0.05 are considered statistically significant
and no adjustments have been made for multiple comparisons.
RESULTS
There were 806 surgical resections for lung cancer in
the MMA-QSR cohort during the period of interest. Sixty
patients (7.4%) who had received preoperative chemotherapy
and/or radiation therapy were excluded from analysis because
of the possible impact of such treatment on the pathologic
stage of disease, leaving a total of 746 patients in the analysis
cohort. Five hundred six patients (67.8%) had at least one LN
examined and no LN metastasis (pN0); 90 patients (12.1%)
had surgical resection and no LNs examined (pNx). The
remaining 150 patients (20.1%) had node-positive disease.
These patients are excluded from further discussion.
Patient Demographics and Disease
Characteristics
The demographic characteristics were identical be-
tween patients who underwent surgical resection with nega-
tive LN examination and those who had no LNs examined
(Table 1). The median age of the pN0 cohort was 68.1 (range,
42.0–89.4) years, and that of the pNx cohort was 69.8
(36.9–87.1) (p  0.20). There was no difference in the
histologic pattern of disease between patients in the two
groups. Most patients had adenocarcinoma and squamous cell
carcinoma; 6.5% of patients with pN0 had bronchioloalveolar
cell carcinoma, compared with 10.0% of patients with pNx.
As expected in a surgical resection cohort, few patients had
small cell lung cancer.
There were differences in the T-stage characteristics of
patients. Although 87.8% in the N0 and 90.0% of patients in
TABLE 1. Characteristics of 596 Patients with Pathologic
Nx or N0 Lung Cancer
Variable
N0
(N  506)
n (%)
Nx
(N  90)
n (%) p
Age, yr 0.49
45 8 (1.6) 2 (2.2)
45–70 292 (57.7) 46 (51.1)
70 206 (40.7) 42 (46.7)
Gender 0.16
Female 240 (47.4) 50 (55.6)
Male 266 (52.7) 40 (44.4)
Race 1.00
African American 106 (21) 19 (21.1)
White 397 (78.5) 71 (78.9)
Other 3 (0.6) 0 (0)
Health insurance
status
0.93
Commercial 153 (30.2) 29 (32.2)
Medicaid 23 (4.6) 4 (4.4)
Medicare 304 (60.1) 54 (60)
None/other 26 (5.1) 3 (3.3)
Histology 0.9
Adenocarcinoma 218 (43.1) 39 (43.3)
Squamous 192 (37.9) 32 (35.6)
Bronchioloalveolar 33 (6.5) 9 (10)
Large cell 26 (5.1) 2 (2.2)
Adenosquamous 15 (3.0) 4 (4.4)
Other 16 (3.2) 1 (1.1)
Small cell 6 (1.2) 3 (3.3)
Stage 0.0006
T1 250 (49.4) 65 (72.2)
T2 194 (38.3) 16 (17.8)
T3 18 (3.6) 3 (3.3)
T4 40 (7.9) 4 (4.4)
TX 4 (0.8) 2 (2.2)
M1 4 (0.8) 2 (2.2)
M0 502 (99.2) 88 (97.8)
Extent of resection 0.0001
Bilobectomy 32 (6.3) 1 (1.1)
Lobectomy 406 (80.2) 40 (44.4)
Pneumonectomy 40 (7.9) 0 (0)
Segmentectomy 9 (1.8) 2 (2.2)
Wedge resection 19 (3.8) 47 (52.2)
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the pNx group had pT1/pT2 disease, a higher proportion of
patients in the pNx group had pT1 lesions (72.2% versus
49.4%), whereas more patients in the pN0 group had pT2
lesions (38.3% versus 17.8%). These differences were statis-
tically significant (p  0.001). The proportion of patients
with T3 and T4 diseases was equally small in both groups of
patients (Table 1).
Details of Surgery
All operations were performed by surgeons who were
board certified in cardiothoracic surgery. No patients in the
cohort had their lung resection surgery performed by general
surgeons or nonboard-certified surgeons. The extent of surgical
resection was significantly different between the two groups
(Table 1). A higher proportion of patients in the pNx cohort had
sublobar (either wedge or segmental) resection, 54.4% com-
pared with 5.8% (p 0.0001). There were no pneumonectomies
performed in the pNx group and 40 (7.9%) in the pN0 group.
Interestingly, 45% of the pNx group had adequately extensive
lung resection (bilobectomy or lobectomy) to suggest that in-
trapulmonary (N1) LNs should have been present in the resec-
tion specimen, even if no mediastinal LNs were submitted by the
surgeon. This raises questions about the contribution of pathol-
ogists to suboptimal LN examination.
The details of LN examination in the pN0 group are
presented in Table 2. The overall number of LNs examined
was relatively low, with a median of 5. The median number
of N2 LNs examined in the pN0 cohort was only 1, and
35.4% of patients had no mediastinal LN material examined,
potentially exposing them all to the danger of underestima-
tion of pN stage. Curiously, 9% of patients with pN0 disease
had no N1 LNs examined, not only potentially missing N1
disease but also again raising the question of thoroughness of
pathologic examination, because 35 of 46 of these patients
(76.1%) had sufficiently extensive lung resection to suggest that
intrapulmonary (stations 12–14) LNs would be present in the
lung resection specimen, irrespective of the surgeon’s effort to
specifically isolate them. Only 55.5% of pN0 patients had LNs
examined from both N1 and N2 LN stations, despite this being
the recommended extent of LN examination. However, even this
group had a median of only seven LNs examined overall. In fact,
21% of pN0 patients had only 1 or 2 LNs examined and 85%
had 10 or fewer LNs examined.
Outcomes
The overall survival estimates of the two groups are
compared in Table 3. The 30-day survival (standard error) of
patients in the pNx versus pN0 group was 0.95 (0.03) and
0.96 (0.01), respectively. The unadjusted 3-year survival of
patients in the pNx versus pN0 group was 0.62 (0.07) versus
0.70 (0.02). This difference was not significant (log-rank p
value  0.19). When adjusted for T stage (Figure 1), the
3-year survival estimate for the T1NxM0 versus T1N0M0
patients was 70% versus 79% (p 0.17); for T2NxM0 versus
T2N0M0, it was 25% versus 65% (p 0.01). There were too
few patients with T3NxM0 and T4NxM0 for survival com-
parison. In the Cox proportional hazards model, nodal status
and T stage remained significantly associated with survival
(Table 4). The hazard ratio of the pN0 group compared with
pNx was 0.59 (p  0.036) when controlling for T stage and
type of resection (sublobar, yes/no).
The 3-year survival of patients in the pN0 group who
had only N1 LNs examined was 70%; for those with only N2
LNs examined, it was 77%; and it was 67% for those with
both N1 and N2 LNs examined. The survival experience of
these groups was not significantly different (p  0.53). There
remained no difference even after adjustment for T stage. In
the multiple variable analysis, T stage was significantly
associated with outcome (p  0.01). Neither the location of
LNs examined (N1 only, N2 only, or N1 and N2) nor the
extent of resection was a significant determinant of outcome.
CONCLUSIONS
We created the MMA-QSR cohort to enable us closely
examine the factors that underlie the reported variation in
quality and outcomes of surgical resection for lung cancer, as
part of a much-needed national quality-improvement process
in lung cancer care.21 Our cohort is comparable with the
TABLE 2. Details of Lymph Node Examination in pN0
Cohort
Lymph Node
Examination Parameter
Median
(Range)
N with
Parameter Percent
All lymph node stations 5 (1–45) 506 100
Peripheral nodes (N1) 3 (0–38)
Mediastinal nodes (N2) 1 (0–29)
Only N1 nodes examined 3 (1–18) 179 35.4
Only N2 nodes examined 2 (1–13) 46 9.1
Both N1 and N2 nodes
examined
7 (2–45) 281 55.5
Total no. lymph nodes
1–10 430 85.0
11–14 47 9.3
15–16 9 1.8
16 20 4.0
TABLE 3. Stage-Dependent Survival Estimates
Stage Group (N)
Survival Estimates
(Standard Error)
Log-Rank
p1 Year 2 Year 3 Year
T1NXMX (54) 0.83 (0.05) 0.74 (0.06) 0.70 (0.07) 0.0113
T2NXMX (12) 0.58 (0.14) 0.50 (0.14) 0.25 (0.19)
T1N0MX (221) 0.88 (0.02) 0.82 (0.03) 0.79 (0.03) 0.001
T2N0MX (182) 0.81 (0.03) 0.72 (0.04) 0.65 (0.04)
T3N0MX (17) 0.65 (0.12) 0.65 (0.12) 0.65 (0.12)
T4N0MX (32) 0.72 (0.08) 0.60 (0.09) 0.44 (0.10)
T1NXMX (54) 0.83 (0.05) 0.74 (0.06) 0.70 (0.07) 0.17
T1N0MX (221) 0.88 (0.02) 0.82 (0.03) 0.79 (0.03)
T2NXMX (12) 0.58 (0.14) 0.50 (0.14) 0.25 (0.19) 0.0086
T2N0MX (182) 0.81 (0.03) 0.72 (0.04) 0.65 (0.04)
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general population of patients undergoing surgical resection
for NSCLC in the United States. The demographic charac-
teristics are similar, except for the higher proportion of black
patients, which reflects the demographic features of a south-
ern U.S. population.16,21 However, unlike the general U.S.
experience in which 24 to 36% of all lung resections are
performed by general surgeons,22,23 all patients in the MMA-
QSR cohort had their resection performed by board-certified
cardiothoracic or general thoracic surgeons. This suggests
that the overall quality of resection is likely no worse than in
the average U.S. population. Indeed, the impact of surgeon
specialty on short and long-term survival is such that our
cohort might even be better.22–24
A comparison of key quality resection parameters in the
MMA-QSR pN0/pNx cohort to a National Cancer Database
(NCDB) cohort21 with stage I disease shows that our pneu-
monectomy (6.7% versus 7.7%) and wedge resection (11.1%
versus 17.1%) rates are comparable. Although it is alarming
that 45% of our pNx/pN0 cohort had no mediastinal LNs
examined, this is similar to the NCDB data in which 42.2%
of the whole cohort had the same problem. Indeed, the full
MMA-QSR cohort in which 30.8% did not have mediastinal
LNs examined compares favorably with the broader U.S.
experience reported by the NCDB.
In a landmark retrospective analysis of the Surveil-
lance, Epidemiology and End-Results (SEER) database, in
which all patients with pNx disease were excluded, Ludwig et
al. found an increase in survival with increasing number of
LNs evaluated after definitive surgery for stage I NSCLC,
with a peak at about 13 to 16 LNs. They suggested that
between 11 and 16 LNs need to be evaluated to assure node
negativity.16 In this SEER cohort, 41.8% had 1 to 4 LNs,
72.1% had 1 to 8 LNs, 14.7% had 9 to 12, and 5.8% had 13
to 16 LNs examined. In our pN0 cohort, 43.3% had 1 to 4;
75.9% had 1 to 8; 15.0% had 9 to 12; and 5.1% had 13 to 16
LNs examined. It seems, therefore, that the MMA-QSR
cohort is reasonably reflective of the U.S. experience and our
findings are likely to be generalizable.
It is disappointing that 12% of patients undergoing
surgical resection for NSCLC have no LNs examined. It is
interesting that most of these patients had a sublobar resec-
tion. It is equally interesting to note that a significantly higher
percentage of patients in the pNx group had T1 lesions,
compared with pN0 patients. It is not clear whether this
reflects a practice of limiting the extent of lung resection
because of limited residual lung function and/or excessive
comorbidity, or whether there is a practice trend to perform
sublobar resections in patients with relatively smaller lesions,
FIGURE 1. Kaplan-Meier survival curves for patients with T1N0, T1Nx, T2N0, and T2Nx non-small cell lung cancer in the
Memphis Metropolitan Area Quality of Surgical Resection cohort.
TABLE 4. Multivariate Analysis of Survival Differences
Multiple Variable Cox PH Model
Variable p
Survival comparisons between pN0 and pNx
N0/NX 0.0363
T stage 0.0012
Sublobar (yes/no) 0.65
Survival comparisons between pN0 patients with
N1 only, N2 only and N1  N2 nodes
Level 1 only/level 2 only/levels 1 and 2 0.80
T stage 0.0031
Sublobar (yes/no) 0.82
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or both. Unfortunately, we did not have access to preopera-
tive pulmonary function studies that would have enabled us to
examine for any differences in pulmonary function between
the two groups. However, all demographic characteristics,
including age, race, and gender, which may be associated
with comorbid risk, were similar between the two groups of
patients (Table 1).
Our findings are very similar to those of Varlotto et al.25
in their retrospective review of patients in the SEER database
who had resection for stage I NSCLC from 1992 to 2002, in
which they found that 13% had pNx. Seventy percent of this
cohort had received sublobar resection and the median lesion
size of this group (20 mm) was significantly less than that of
the full pN0 cohort (25 mm). Furthermore, 49% of this SEER
cohort had no mediastinal LN examination, similar to the
45% in the MMA-QSR cohort, and the median number of
LNs examined in the pN0 cohort was 5, which is identical to
our findings.
Although the Lung Cancer Study Group report that the
outcome after sublobar lung resection is inferior to that after
lobectomy led to the adoption of lobectomy as the recom-
mended extent of resection,15,26 there continues to be a debate
in the thoracic surgery community about the role of sublobar
resection in patients with small, peripheral lung cancers.27,28
This is the focus of an ongoing Cancer and Leukemia Group
B study (clinicaltrials.gov identifier NCT00499330). Until
results of this trial are available, it seems prudent to recom-
mend lobectomy as the resection extent of choice for lung
cancer, except in the case of limited lung function. However,
even patients who undergo sublobar resections should have
thorough evaluation of their LNs to the same extent as those
with lobectomy. The safety of LN dissection or sampling in
patients who have limited lung function is not of major
concern. Comorbidity and limited lung function do not sig-
nificantly alter either the risk or benefit of adequate lymph
nodal examination in patients who undergo a wedge resection
for NSCLC. Our findings may indicate misunderstanding of
the need for LN examination in all patients who undergo
potentially curative surgery for lung cancer.
Our study also points to the potential involvement of
pathologists in the problem of suboptimal LN staging. Pa-
tients who have adequate lung tissue resected to assure the
presence of intrapulmonary LNs would be expected to have
those nodes available for examination, even if the surgeon did
not dissect them out of the submitted resection material.
Pathologists are expected to specifically seek these out. We
found a large proportion of cases (44% of pNx and 9% of
pN0) in which the pathologist did not search for such LNs.
This is significant because it points to an opportunity for
successful intervention in the pathology laboratory.
In the end, our most important finding is the disparity in
survival between the two cohorts. Comparison of the 3-year
survival of the MMA-QSR cohort with the cohort of Clifton
Mountain that was used to develop the sixth AJCC lung
cancer staging criteria7 is very instructive. The MMA-QSR
pT1N0M0 survival estimate (79%) is similar to the Mountain
cohort (80%); as is pT2N0M0 (65%, MMA versus 67%,
Mountain). This corroborates our earlier argument that the
MMA-QSR cohort approximates the general U.S. experience.
The survival of the T1NxM0 group (70%) is closer to that of
T2N0M0 group of Mountain. The survival (25%) of
T2NxM0 group is worse than that of T1–3N2M0 cohort
(32%) of Mountain. This observation may be explained by
the fact that about 46% of patients with pT2 NSCLC who
undergo careful LN examination have node-positive disease,
including 24% with N2 disease; 29% of those with pT1 have
nodal involvement, 19% having pN1, and 10% pN2 disease.9
However, it is also possible that the pNx group had signifi-
cantly worse lung function, which was why so many of them
had sublobar resection in the first place. It is also possible that
they had other unexplained significant comorbidities that
account for their higher mortality rate. However, it is notable
that the 30-day postoperative mortality rate was identical
between the two groups, as well as key demographic charac-
teristics such as age, gender, and race, that can point indi-
rectly to the likelihood of comorbidity. However, updates of
the MMA-QSR database will attempt to incorporate informa-
tion on comorbidities and preoperative pulmonary function in
a bid to adjust future analyses for preoperative risk.
Nodal staging of patients in the MMA-QSR cohort was
very poor. Neither demographic nor disease factors account
for this. The failure to show a difference in outcomes between
the pN0 patients who had only N1 or N2 or both N1 and N2
LNs examined, although somewhat surprising, may simply
reflect this fact. The low number of LNs examined suggests that
the predominant type of intraoperative LN examination proce-
dure was random sampling, which is known to yield outcomes
inferior to those of systematic sampling or complete mediastinal
LN dissection.29 Indeed, the median number of LNs examined in
the pN0 group (five) is less than the minimum recommended by
the International Association for the Study of Lung Cancer in the
seventh AJCC staging system (six). It is significantly less than
the evidence that suggests that the optimum number of LNs
required to declare node negativity after resection of NSCLC is
in the range of 11 to 16.16,25 Thus, small, innocuous-looking LNs
with metastases may have been left behind in each of the
subgroups of patients with pN0, thereby negating the effect of
sampling location.
The use of wedge resection is frequently associated with
failure to identify LNs for examination. However, 45% of
patients in the pNx group had received a lobectomy or bilobec-
tomy, which suggests that pathologists also fail to isolate LNs
for examination from adequately resected specimens. Most pa-
tients with node-negative disease have fewer than 10 nodes, and
a large proportion have no mediastinal LNs examined (Table 2).
This raises the possibility of understaging.
Patients with pT2 NSCLC who have surgical resection
without LN examination are an especially vulnerable popu-
lation. Estimation of their prognosis should take this fact into
account. Their postoperative management should be designed
to mitigate the danger from the high risk of undiagnosed LN
involvement.
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